Evidence map›Paper›PMID 26870203›Full record

ArticleOncology letters2016

GADD45A expression is correlated with patient prognosis in esophageal cancer.

Hideyuki Ishiguro, Masahiro Kimura, Hiroki Takahashi, Tatsuya Tanaka, Koji Mizoguchi, Hiromitsu Takeyama

Abstract read
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. GADD45 in Stress Signaling, Cell Cycle Control, and Apoptosis.Advances in experimental medicine and biology · 2022
    Article
  8. Combined Use of Three Machine Learning Modeling Methods to Develop a Ten-Gene Signature for the Diagnosis of Ventilator-Associated Pneumonia.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hideyuki IshiguroDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medical Science, Nagoya, Aichi 467-8601, Japan.
Masahiro KimuraDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medical Science, Nagoya, Aichi 467-8601, Japan.
Hiroki TakahashiDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medical Science, Nagoya, Aichi 467-8601, Japan.
Tatsuya TanakaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medical Science, Nagoya, Aichi 467-8601, Japan.
Koji MizoguchiDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medical Science, Nagoya, Aichi 467-8601, Japan.
Hiromitsu TakeyamaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medical Science, Nagoya, Aichi 467-8601, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of patients with esophageal cancer remains poor, and the tumor-node-metastasis classification system is not sufficient for predicting patient prognoses. Therefore, the identification of novel predictive markers for esophageal cancer is required. The present study investigated the clinicopathological significance of growth arrest and DNA damage-inducible 45α (GADD45A) and p53 in resectable esophageal squamous cell carcinoma (ESCC). The study consisted of 62 patients with esophageal cancer who underwent surgery between 2001 and 2007. The expression of the

Indexed as

esophageal cancerGADD45Aimmunohistochemistryp53prognosis

Identifiers

PMID26870203
PMCPMC4727128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.